ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data

Tracy Staton You missed the American College of Cardiology meeting. That's OK. The most newsworthy research coming out of the meeting is gathered right here, with almost every Big ...

Lilly and Merck pair ‘breakthrough’ therapies in latest cancer collaboration

Damian Garde Eli Lilly and Merck are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy. FierceBiotech ...

Mylan latest caught up in DOJ probe of generic drug prices

Eric Palmer Mylan said today that it got a special delivery from the Justice Department Thursday, making it the most recent of a string of drugmakers to get a subpoena from federal ...

FierceBiotech radio on GSK’s latest setback, Kyle Bass’ ‘truthful irrelevancy,’ and Horizon’s web presence

Alok Saboo FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the latest setback in a bad run of form for GlaxoSmithKline, Kyle Bass' trouble with drug ...

UPDATED: Heard the latest Kite Pharma rumor? CEO says it ain’t so

John Carroll Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax. FierceBiotech News

Boehringer takes a neuroscience approach to obesity with latest deal

Damian Garde Boehringer Ingelheim is pairing up with a small California biotech to explore the role circuits in the nervous system play in obesity, scouting for drug targets that could ...

Gilead takes a $125M FDA shortcut with its latest HIV combo

Damian Garde Last year, Gilead Sciences paid $ 125 million for a ticket promising a speedy FDA review. Now the Big Biotech is cashing it in, submitting a combination HIV treatment ...

Shire’s Lialda, Gattex are hedge funder’s latest patent targets

Tracy Staton Hedge fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics drug, Bass asked the U.S. Patent ...

Lilly’s new insulin is likely DOA after latest delay, analyst says

Damian Garde Eli Lilly's already-delayed new insulin has run into another roadblock, as potentially harmful liver side effects have sent the company back to the clinic, putting ...

Point-of-care marketing shoots past DTC as pharma’s latest marketing trend

Emily Wasserman Point-of-care marketing is shooting past direct-to-consumer advertising as pharma marketing's latest trend.  FiercePharma News

INC banks $150M in the latest big CRO IPO

Damian Garde INC Research is the latest among Big Pharma's biggest contractors to pull off an IPO, raising $ 150 million and joining its largest rivals on Wall Street. FierceBiotech ...

FDA pulls back the curtain on Sarepta’s latest DMD delay

Damian Garde In an uncommon move, the FDA has publicly weighed in on an in-development drug, clarifying the status of Sarepta Therapeutics' closely watched Duchenne muscular dystrophy ...
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS